Related Experiment Video

Updated: Feb 24, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K

HDAC inhibitors: A new promising drug class in anti-aging research

Elena G Pasyukova1, Alexander M Vaiserman2

  • 1Institute of Molecular Genetics, RAS, Moscow, Russia.

Mechanisms of Ageing and Development
|August 28, 2017
PubMed

Insights

Histone deacetylase (HDAC) inhibitors show promise in combating aging and related diseases. This review explores their healthspan-promoting and life-extending effects in animal and human studies.

Area of Science:

  • Epigenetics and molecular biology
  • Gerontology and aging research

Background:

  • Epigenetic regulation influences aging processes like frailty and genomic instability.
  • Aging is linked to diseases including atherosclerosis, diabetes, cancer, and neurodegeneration.
  • Histone deacetylase (HDAC) inhibitors are emerging as potential therapeutics for aging.

Purpose of the Study:

  • To review literature on the healthspan-promoting effects of HDAC inhibitors.
  • To examine the life-extending properties of HDAC inhibitors in various studies.

Main Methods:

  • Literature review of scientific articles.
  • Analysis of data from animal models and clinical studies.

Main Results:

  • HDAC inhibitors demonstrate significant healthspan and lifespan benefits.
  • Evidence supports the therapeutic potential of HDAC inhibitors in combating aging.

Conclusions:

  • HDAC inhibitors represent a promising therapeutic strategy for age-related decline.
  • Further research into HDAC inhibitors could lead to interventions against aging and associated diseases.
Keywords:
Aging-related diseaseEpigeneticsHDAC inhibitorHealthspanLifespan extensionLongevity

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Measuring Single-Cell Aging with an Imaging-based Biomarker of Chromatin and Epigenetic Aging09:10

Measuring Single-Cell Aging with an Imaging-based Biomarker of Chromatin and Epigenetic Aging

Published on: January 30, 2026

545

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
257
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
750
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
309
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K